Tyrosin plus Vitamin C – ein mögliches nutritiv-präventives Konzept beim Morbus Parkinson im Frühstadium

Zusammenfassung

Zur Therapie der Parkinson-Erkrankung wird meist die Vorstufe des Dopamins, L-DOPA, eingesetzt, was allerdings längerfristig zu einem vermehrten oxidativen Stress führen kann. Daher erscheint es sinnvoll, mit der DOPA-Therapie verzögert zu beginnen. Ein nutritiv-präventives Ernährungskonzept könnte einerseits die endogene Dopamin-Produktion fördern und gleichzeitig den oxidativen Stress reduzieren.

Abstract

In the treatment of Parkinson‘s disease, usually the precursor of dopamine, L-DOPA, is used. However, this can lead to increased oxidative stress in the longer term. Therefore, it seems to be reasonable to start the DOPA therapy with a delay. A nutritive as well as preventive nutritional concept could enhance the endogenous dopamine production and at the same time reduce the oxidative stress.

Schlüsselwörter

Morbus Parkinson - L-DOPA - Therapie - präventives Ernährungskonzept - endogene Dopamin-Produktion - Dopamin-Synthese - Vitamin C - Tyrosin

Key words

Parkinson‘s disease - L-DOPA - therapy - preventive nutritional concept - endogenous dopamine production - dopamine synthesis - vitamin C - tyrosine

• Literatur

• 1 Tsai MJ, Lee EHY. Characterization of L-DOPA transport in cultured rat and mouse astrocytes. J Neuroscience Res 1998; 43: 490-495
• 2 del Amo EM, Urtti A, Yliperttula M. Pharmakinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 2008; 35: 161-174
• 3 Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson’s disease: Evidence supporting it. Ann Neurol 1992; 32: 804-812
• 4 Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: University Press; 2015
• 5 Martin HL, Teisman P. Glutathione – a review on its role and significance in Parkinson’s disease. FASEB J 2009; 23: 3263-3272
• 6 Fahn S. An open trial of high-dosage antioxidants in early Parkinson’s disease. Am J Clin Nutr 1991; 53: 380S-382S
• 7 Nagatsu T, Nakashima A, Ichinose H. et al. Human tyrosine hydroxylase in Parkinson’s disease and in related disorders. J Neural Transm 2019; 126: 397-409
• 8 Tabrez S, Jabir NR, Shakil S. et al. A synopsis on the role of tyrosine hydroxylase in Parkinson’s disease. CNS Neurol Discord Drug Targets 2012; 11: 395-409
• 9 Vrecko K, Storga D, Birkmayer GJD. et al. NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaeochromocytoma cells. Biochem Biophys Acta 1997; 1361: 59-65
• 10 Birkmayer GJD, Birkmayer W. Stimulation of endogenous L-dopa biosynthesis – a new principle for the therapy of Parkinson’s disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH). Acta Neurol Scand 1989; 126: 183-187
• 11 Bruchelt G, Kuçi Z, Niethammer D. et al. Die Rolle von Vitamin C beim Catecholaminstoffwechsel. VitaMinSpur 2000; 15: 73-76
• 12 Lehninger AL, Nelson DL, Cox MM. Prinzipien der Biochemie. Heidelberg, Berlin, Oxford: Spektrum Akademischer Verlag; 1994
• 13 Davies MB, Austin J, Partridge DA. Vitamin C: Its Chemistry and Biochmistry. Cambridge UK: Royal Society of Chemistry Paperbacks; 1991
• 14 Werner ER, Blau N, Thöny B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 2011; 438: 397-414
• 15 d’Uscio LV, Milstien S, Richardson D. et al. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 2003; 92: 88-95
• 16 Seitz G, Gebhardt S, Beck JF. et al. Ascorbic acid stimulates DOPA synthesis and tyrosine hxdroxylase gene expression in the human neuroblastoma cell line SK-N-SH. Neurosci Letters 1998; 244: 33-36
• 17 Huang A, Vita JA, Venema RC. et al. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 2000; 275: 17399-17406
• 18 Heller R, Unbehaun A, Schellenberg B. et al. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 2001; 276: 40-47
• 19 Kuçi Z, Ehrlichmann W, Sauer J. et al. Fast enzymatic synthesis of n. c. a. 6-[¹⁸ F]fluorodopamine (FDA) from n. c. a. 6-[¹⁸ F] FDOPA and the fate of 6-FDOPA and 6-FDA in neuroblastoma and Caki-1 cells after their uptake. J Label Compd Radiopharm 2019; 62: 438-447
• 20 Biesalski HK, Grimm P, Nowitzki-Grimm S. Taschenatlas Ernährung. Stuttgart, New York: Thieme; 2015
• 21 Huang J, Agus DB, Winfree ChJ. et al. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. PNAS 2001; 98: 11720-11724
• 22 Wilgus H, Rokoski R. Inactivation of tyrosine hydroxylase by ascorbate in vitro and in PC-12 cells. J Neurochem 1988; 51: 1232-1239
• 23 Kuzkaya N, Weissmann N, Harrison DG. et al. Interaction of peroxinitrite, tetrahydrobiopterin, ascorbic acid, thiols. J Biol Chem 2003; 278: 22546-22554
• 24 Mahoney-Sánchez L, Bouchaoui H, Ayton S. et al. Ferroptosis and its potential role in the physiopathology of Parkinson’s disease. Prog Neurobiol 2021; 196: 101890
• 25 Pifl Ch, Rajput H, Blesa J. et al. Is Parkinson’s disease a vascular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J Neurosci 2014; 34: 810-818